Related Experiment Video
Updated: Jan 24, 2026
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Shifting Thresholds: Changes in Antihypertensive Eligibility Under the 2025 Versus 2017 Hypertension Guidelines
Faith E Metlock1, Bede N Nriagu1, Britton Scheuermann2
1Inova Schar Heart and Vascular, Inova Health System, Falls Church, USA.
Insights
The 2025 hypertension guidelines show minimal change in treatment eligibility, affecting about 400,000 adults. This study analyzed the impact of new guidelines on antihypertensive therapy for U.S. adults.
Area of Science:
- Cardiovascular Medicine
- Public Health
- Clinical Guidelines
Background:
- Hypertension impacts nearly half of U.S. adults, necessitating updated treatment guidelines.
- The 2025 ACC/AHA guideline introduces the PREVENT risk equations and revised stage 1 hypertension treatment recommendations.
- These changes may alter eligibility for antihypertensive therapy.
Purpose of the Study:
- To quantify changes in antihypertensive treatment eligibility between the 2025 and 2017 guidelines.
- To characterize newly eligible adults and assess eligibility concordance.
- To evaluate the robustness of findings across different PREVENT model variants.
Main Methods:
- A simulation-based analysis using National Health and Nutrition Examination Survey data (2017-2020) for adults aged 30-79.
- Treatment eligibility was determined using 2017 and 2025 guideline criteria.
- Analyses incorporated multiple PREVENT risk equation variants and multivariable modeling.
Main Results:
- A minimal net increase of 0.7% (approx. 400,000 adults) in treatment eligibility was observed under the 2025 guidelines.
- Most adults remained consistently ineligible (63.3%) or eligible (36.3%).
- Newly eligible individuals were typically older women with higher BMI and borderline glycemic measures.
Conclusions:
- The 2025 ACC/AHA guideline adoption results in a minimal expansion of antihypertensive treatment eligibility.
- Findings were consistent across various PREVENT model variants, supporting risk-based implementation.
- The study supports the adoption of risk-based strategies for guideline implementation.
Background:
Hypertension affects nearly half of U.S. adults. The 2025 American College of Cardiology/American Heart Association guideline adopts the Predicting Risk of Cardiovascular Disease Events (PREVENT) risk equations and updates treatment recommendations for stage 1 hypertension, potentially altering eligibility for antihypertensive therapy.
Objectives:
The primary objective was to quantify changes in antihypertensive treatment eligibility under the 2025 vs 2017 guidelines. Secondary objectives were to characterize adults newly meeting treatment thresholds, assess concordance and discordance in eligibility, and evaluate robustness across PREVENT model variants.
Methods:
We conducted a simulation-based analysis using nationally representative National Health and Nutrition Examination Survey data (2017-2020) among adults aged 30 to 79 years. Treatment eligibility was assigned using 2017 and 2025 guideline criteria. Survey-weighted estimates quantified population-level eligibility, newly eligible adults, and concordance patterns. Analyses were repeated using PREVENT Base, Full, hemoglobin A1c, and albumin-to-creatinine ratio variants, and multivariable models identified predictors of eligibility.
Results:
Among 5,578 adults (weighted population 160 million), 36.4% were eligible for treatment under the 2017 guideline and 36.6% under the 2025 guideline, representing a minimal net increase of 0.7% (approximately 400,000 adults). Most adults were consistently ineligible (63.3%), whereas one-third were consistently eligible (36.3%). Newly eligible adults were predominantly older women with higher body mass index and borderline glycemic measures but without established cardiovascular disease. Eligibility patterns were stable across racial and ethnic groups. Analyses were repeated across all PREVENT risk equation variants, and multivariable models identified predictors of eligibility.
Conclusions:
Adoption of the 2025 American College of Cardiology/American Heart Association guideline results in a minimal expansion of antihypertensive treatment eligibility. Results were robust across PREVENT model variants, supporting risk-based guideline implementation.
More Related Videos
10:42A Postoperative Evaluation Guideline for Computer-Assisted Reconstruction of the Mandible
Published on: January 28, 2020
08:52Psychophysical Tracking Method to Assess Taste Detection Thresholds in Children, Adolescents, and Adults: The Taste Detection Threshold TDT Test
Published on: April 21, 2021
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
01:16Antihypertensive Drugs: Action of Diuretics
01:26Guidelines for Nursing Documentation II
Timely documentation is crucial to ensure continuity of care for patients. Any delays in recording or reporting medical information can result in medical errors and even adverse patient outcomes. From medication administration to diagnostic test results, every detail must be accurately and promptly documented to provide the best possible care for patients.
01:06Legal Guidelines for Documentation
01:23Guidelines for Sketching a Curve
01:11Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...